Hong Wan

619 total citations
23 papers, 488 citations indexed

About

Hong Wan is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hong Wan has authored 23 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 7 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hong Wan's work include Phagocytosis and Immune Regulation (13 papers), Immunotherapy and Immune Responses (12 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Hong Wan is often cited by papers focused on Phagocytosis and Immune Regulation (13 papers), Immunotherapy and Immune Responses (12 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Hong Wan collaborates with scholars based in United States, South Korea and Sweden. Hong Wan's co-authors include Jaume Pons, Tracy C. Kuo, Ann‐Beth Jonsson, Ons Harrabi, Amy Chen, Emma Sangalang, Laura V. Doyle, Steven E. Kauder, Sangeetha Bollini and Bora Han and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hong Wan

21 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hong Wan United States	12	368	133	87	83	68	23	488
Louise A. Jopling United Kingdom	11	316 0.9×	233 1.8×	160 1.8×	24 0.3×	87 1.3×	14	502
Simone Meuter Switzerland	8	470 1.3×	169 1.3×	17 0.2×	42 0.5×	73 1.1×	9	582
Florian Schiemann Germany	6	287 0.8×	115 0.9×	52 0.6×	32 0.4×	62 0.9×	7	394
Yanggu Shi United States	9	187 0.5×	79 0.6×	70 0.8×	11 0.1×	257 3.8×	11	517
Astrid Lanoue United Kingdom	6	541 1.5×	85 0.6×	17 0.2×	20 0.2×	136 2.0×	6	639
Mauritius Menges Germany	6	745 2.0×	89 0.7×	33 0.4×	10 0.1×	110 1.6×	7	815
Anne‐Laure Puaux France	8	289 0.8×	90 0.7×	33 0.4×	7 0.1×	108 1.6×	12	421
R.H. van den Berg Netherlands	9	290 0.8×	29 0.2×	21 0.2×	91 1.1×	96 1.4×	13	437
Aya Obata-Onai Japan	5	903 2.5×	114 0.9×	24 0.3×	27 0.3×	143 2.1×	5	993
Kaveh Abdi United States	11	309 0.8×	49 0.4×	25 0.3×	14 0.2×	79 1.2×	24	456

Countries citing papers authored by Hong Wan

Since Specialization

Citations

This map shows the geographic impact of Hong Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Wan more than expected).

Fields of papers citing papers by Hong Wan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Wan. The network helps show where Hong Wan may publish in the future.

Co-authorship network of co-authors of Hong Wan

This figure shows the co-authorship network connecting the top 25 collaborators of Hong Wan. A scholar is included among the top collaborators of Hong Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong Wan. Hong Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Henry, Jason T., Anna C. Pavlick, Sunnie S. Y. Kim, et al.. (2025). Abstract CT045: A phase 1/2 trial of TAC-001 (TLR9 agonist-CD22 mAb) in advanced or metastatic solid tumors. Cancer Research. 85(8_Supplement_2). CT045–CT045.

Chen, Amy, Ons Harrabi, Min Li, et al.. (2024). Abstract 6746: A B-cell targeted TLR9 agonist antibody conjugate potentiates cancer vaccine efficacy and rejuvenates vaccine responses in the elderly. Cancer Research. 84(6_Supplement). 6746–6746. 1 indexed citations

Wang, Jing, Shaodong Zhang, Hong Wan, et al.. (2022). A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1. Frontiers in Oncology. 12. 836257–836257. 7 indexed citations

Lee, Keun-Wook, Hyun Cheol Chung, Tae Min Kim, et al.. (2021). 498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01. SHILAP Revista de lepidopterología. 6 indexed citations

Harrabi, Ons, Amy Chen, Emma Sangalang, et al.. (2021). 780 ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity. SHILAP Revista de lepidopterología. A815–A815. 3 indexed citations

Kuo, Tracy C., Amy Chen, Ons Harrabi, et al.. (2020). Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology & Oncology. 13(1). 160–160. 58 indexed citations

Harrabi, Ons, Amy Chen, Emma Sangalang, et al.. (2020). 615 Targeted immune cell activation by systemic delivery of toll-like receptor 9 agonist antibody conjugates induce potent anti-tumor immunity. SHILAP Revista de lepidopterología. A369.2–A370.

Chow, Laura Q.M., Justin F. Gainor, Nehal J. Lakhani, et al.. (2020). A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. Journal of Clinical Oncology. 38(15_suppl). 3056–3056. 18 indexed citations

Kim, Tae Min, Nehal J. Lakhani, Justin F. Gainor, et al.. (2020). ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 13–14. 23 indexed citations

10.

Hustinx, Hein, et al.. (2020). Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing. Transfusion. 60(10). 2399–2407. 12 indexed citations

11.

Sockolosky, Jonathan T., Emma Sangalang, Shelley Izquierdo, et al.. (2019). Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα. mAbs. 11(6). 1036–1052. 39 indexed citations

12.

Kim, Tae Min, Nehal J. Lakhani, Justin F. Gainor, et al.. (2019). A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1953–1953. 19 indexed citations

13.

Chow, Laura Q.M., Justin F. Gainor, Nehal J. Lakhani, et al.. (2019). A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. Journal of Clinical Oncology. 37(15_suppl). 2514–2514. 13 indexed citations

14.

Lakhani, Nehal J., Patricia LoRusso, Navid Hafez, et al.. (2018). A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 3068–3068. 14 indexed citations

15.

Kauder, Steven E., Tracy C. Kuo, Ons Harrabi, et al.. (2018). ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE. 13(8). e0201832–e0201832. 121 indexed citations

16.

Kauder, Steven E., Tracy C. Kuo, Amy Chen, et al.. (2017). ALX148 Is a High Affinity Sirpα Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models. Blood. 130. 112–112. 8 indexed citations

17.

Wan, Hong, et al.. (2013). EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2ΔA MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS. Journal of the American College of Cardiology. 61(10). E1387–E1387. 4 indexed citations

18.

Bergman, Peter, Linda Johansson, Hong Wan, et al.. (2006). Induction of the Antimicrobial Peptide CRAMP in the Blood-Brain Barrier and Meninges after Meningococcal Infection. Infection and Immunity. 74(12). 6982–6991. 72 indexed citations

19.

Plant, Laura, Hong Wan, & Ann‐Beth Jonsson. (2006). Non-lipooligosaccharide-mediated signalling via Toll-like receptor 4 causes fatal meningococcal sepsis in a mouse model. Cellular Microbiology. 9(3). 657–669. 7 indexed citations

20.

Johansson, Linda, Anne Rytkönen, Hong Wan, et al.. (2005). Human-Like Immune Responses in CD46 Transgenic Mice. The Journal of Immunology. 175(1). 433–440. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact